Bryan, Garnier & Co announces the successful €18m Private Placement of Nicox

Paris, July 29th, 2016 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful €18 million private placement of Nicox, the international ophthalmic company. Bryan, Garnier & Co acted as Joint Placement Agent alongside Guggenheim Securities LLC.

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced a reserved capital increase of ordinary shares of the company to a specific category of investors. The proceeds from the financing will principally be used to drive the development of NCX 4251, a nanocrystalline formulation of fluticasone for blepharitis, and of NCX 470, a nitric oxide (NO)-donating bimatoprost for intraocular pressure lowering, through proof-of-concept clinical studies.

The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares, which represents the maximum capital increase the company could undertake without publishing a formal prospectus, i.e. 9% of the issued share capital of the company before the capital increase.

The financing attracted significant investor interest in both Europe and the US which exceeded the maximum offering size.

Hervé Ronin, Partner at Bryan, Garnier & Co, emphasized: “This marks the second consecutive equity capital raise Bryan Garnier led for Nicox and demonstrates our commitment to accompany our client. This wall-crossed follow-on was a success in challenging market conditions and anchored with high-quality US and European dedicated healthcare specialist. It is the 3rd largest overnight raise in the French biotech market 2016YTD”

With more than €1.5bn of capital raised since 2014, Bryan Garnier & Co tops the European fundraising league table in healthcare:

· Bryan, Garnier & Co has been involved in several recent IPOs of European healthcare companies on Nasdaq. Amongst the six largest Nasdaq IPOs of European companies, Bryan, Garnier & Co co-led or co-managed: the 100m$ Nasdaq IPO of Celyad (Belgium, May 2015), the $317m Nasdaq IPO of Galapagos (Belgium, April 2015), the $133m IPO of DBV Technologies (France, October 2014), and the $86m IPO and $97m follow-on of LDR Holding (US/France, May 2014).

· Since January 2015, Bryan, Garnier & Co has been also involved in the $245m DBV Technologies public offering, the €25m follow-on of Erytech, the £20m follow-on of Advanced Oncotherapy, the £106m IPO of Quantum Pharma on the London Stock Exchange, a €27m PIPE for Nicox, a €32 PIPE for Cardio3, as well as the €33m IPO of Geneuro and the €37m IPO of Bone Therapeutics on Euronext.

· In 2014, Bryan, Garnier & Co acted as sole placement agent for the €100m growth financing of Merieux Nutrisciences, the largest European healthcare private placement of the year.

For more information, please contact:

Hervé Ronin

Partner – Healthcare Corporate Finance

hronin@bryangarnier.com | + 33 170365722

Pierre Kiecolt-Wahl

Managing Director – Healthcare Equity Capital Markets

pkiecoltwahl@bryangarnier.com | + 33 156687517

Christian Finan

Director – Equity Capital Markets

cfinan@bryangarnier.com | + 33 156687530

Jean de Pracomtal

Associate – Healthcare

jdepracomtal@bryangarnier.com | + 33 156687538

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development, and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.

Nicox’s advanced pipeline features latanoprostene bunod for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, for which a New Drug Application (NDA) was submitted to the FDA by the company’s licensee Bausch + Lomb, Valeant Pharmaceuticals International, Inc.’s, wholly-owned subsidiary. The company’s pipeline also features AC-170, for which the FDA granted priority review for the NDA for the treatment of ocular itching associated with allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite™ for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next-generation ophthalmology-focused candidates, which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.

Nicox is listed on Euronext Paris (Category B: Mid Caps) and is part of the Russell Global, CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.